Publications by authors named "Patrizia Giannatempo"

Claim this Profile
R
Real-world effectiveness of Avelumab maintenance in advanced urothelial carcinoma: results from the Italian multicenter MALVA study (Meet-URO 25).
Giandomenico Roviello, Elisabetta Gambale, Irene De Gennaro Aquino, Marco Maruzzo, Carlo Messina, Patrizia Giannatempo

Oncologist· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Enfortumab Vedotin After Platinum Chemotherapy and Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Real-World Analysis of the ARON-2EV Cohort.
Ondrej Fiala, Francesco Grillone, Kazutoshi Fujita, Enrique Grande, Patrizia Giannatempo

Eur Urol Open Sci· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Redefining Good-prognosis Seminoma: Implications for Clinical Practice of the Updated International Germ Cell Cancer Collaborative Group Classification and Results from the SEMITrends Survey.
Anna Patrikidou, Christoph Oing, Christos Markellos, Axel Heidenreich, Ricardo Leao, Patrizia Giannatempo

Eur Urol Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Medication-related jaw osteonecrosis in metastatic RCC treated with VEGFR-TKIs ± IO and bone agents: A real-world analysis.
Marco Stellato, Ernesto Zecca, Paola Bracchi, Alessandro Rametta, Melanie Claps, Patrizia Giannatempo

Tumori· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guiding first-line treatment decisions in advanced urothelial carcinoma: a global survey.
Enrique Grande, Joaquim Bellmunt, Syed A Hussain, Mubarak M Al Mansour, Aristotle Bamias, Patrizia Giannatempo

Oncologist· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Molecular Androgen and Estrogen Response Scores on Outcomes Following Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer.
Valentina Tateo, Joep J de Jong, Antonio Cigliola, Brigida A Maiorano, Chiara Mercinelli, Patrizia Giannatempo

Clin Cancer Res· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Cyclin-Dependent Kinase 4 Amplifications: A Pioneering Case of Metastatic Leydig Cell Tumor Responding to Abemaciclib.
Amedeo Nuzzo, Marco Barella, Melanie Claps, Matteo Zimatore, Alessandro Rametta, Patrizia Giannatempo

JCO Precis Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Geographical Differences in the Management and Outcomes of Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab After Progression on Platinum-Based Chemotherapy: Results From ARON-2 Study.
Mimma Rizzo, Andrey Soares, Shilpa Gupta, Fabio Calabrò, Hideki Takeshita, Patrizia Giannatempo

JCO Glob Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
mRNA-Based Urine Test Performance in High and Very-High Risk Non-Muscle-Invasive Bladder Cancer Patients Undergoing Contextual Endoscopic Follow-up (VERNAL: Vesical Tumor Early Monitoring: mRNA-Based Follow-up).
Alberto Macchi, Martina Bruniera, Sebastiano Nazzani, Tommaso Ceccato, Claudia Colbacchini, Patrizia Giannatempo

Clin Genitourin Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Organ preservation and oncological efficacy of peniscopically controlled CO laser excision of penile squamous cell carcinoma: Early and late results in a high-volume center.
Sebastiano Nazzani, Vito Lorusso, Mario Catanzaro, Tullio Torelli, Carlo Silvani, Patrizia Giannatempo

Urol Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of Advanced Penile Cancer.
Ramona Stelmach, Patrizia Giannatempo, Nicola Nicolai, Xavier Garcia Del Muro

Oncol Res Treat· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Histology on Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Advanced or Metastatic Urothelial Carcinoma in the Phase 3 KEYNOTE-045 and KEYNOTE-361 Trials.
Patrizia Giannatempo, Jean-Pascal Machiels, Naoto Sassa, Jose Angel Arranz, Yasuhisa Fujii

Clin Genitourin Cancer· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Individualizing first-line treatment for advanced urothelial carcinoma: A favorable dilemma for patients and physicians.
Enrique Grande, Syed A Hussain, Philippe Barthélémy, Ravindran Kanesvaran, Patrizia Giannatempo

Cancer Treat Rev· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab.
Lorena Incorvaia, Sarah Scagliarini, Fernando Sabino Marques Monteiro, Hideki Takeshita, Jose Carlos Tapia, Patrizia Giannatempo

Sci Rep· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2 study.
Ondřej Fiala, Sebastiano Buti, Kazutoshi Fujita, Alfonso Gómez de Liaño, Wataru Fukuokaya, Patrizia Giannatempo

Clin Exp Metastasis· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience.
Mimma Rizzo, Franco Morelli, Yüksel Ürün, Sebastiano Buti, Se Hoon Park, Patrizia Giannatempo

Cancer Med· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hot topics in genitourinary cancers: A multidisciplinary discussion on state-of-the-art and latest developments among international experts and patient advocacy.
Alessandro Rametta, Paolo Ambrosini, Chiara Cavalli, Eleonora Gusmaroli, Melanie Claps, Patrizia Giannatempo

Tumori· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant Chemotherapy VI-RADS Scores for Assessing Muscle-invasive Bladder Cancer Response to Neoadjuvant Immunotherapy with Multiparametric MRI.
Giorgio Brembilla, Giuseppe Basile, Michele Cosenza, Francesco Giganti, Andrea Del Prete, Patrizia Giannatempo

Radiology· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2 Study.
Ondřej Fiala, Francesco Massari, Umberto Basso, Patrizia Giannatempo, Enrique Grande

Target Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 project.
Alessandro Rizzo, Sebastiano Buti, Patrizia Giannatempo, Samer Salah, Javier Molina-Cerrillo

Clin Exp Metastasis· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term survival following anti-PD-(L)1 monotherapy in advanced urothelial cancer and an assessment of potential prognostic clinical factors: a multicentre observational study.
Chantal F Stockem, Sarah M H Einerhand, Isabel Miras Rodríguez, Youssra Salhi, Esther Pérez, Patrizia Giannatempo

BJC Rep· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 Project.
Alessandro Rizzo, Fernando Sabino Marques Monteiro, Yüksel Ürün, Francesco Massari, Se Hoon Park, Patrizia Giannatempo

Target Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neutrophil-to-Eosinophil Ratio Predicts the Efficacy of Avelumab in Patients With Advanced Urothelial Carcinoma Enrolled in the MALVA Study (Meet-URO 25).
Elisabetta Gambale, Marco Maruzzo, Carlo Messina, Irene De Gennaro Aquino, Ismaela Anna Vascotto, Patrizia Giannatempo

Clin Genitourin Cancer· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study.
Mimma Rizzo, Andrey Soares, Enrique Grande, Aristotelis Bamias, Ray Manneh Kopp, Patrizia Giannatempo

Sci Rep· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Uncovering the role of mismatch repair deficiency and microsatellite instability in urothelial carcinoma.
Filippo Ghelardi, Patrizia Giannatempo, Filippo Pietrantonio

BMJ Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis